Skip to main content

Table 4 Study withdrawals during the 21-day stabilization period (ITT Population)

From: Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

Patients withdrawing from study during 21-day stabilization period FP/SAL 250/50 μg (N = 314) SAL 50 μg (N = 325) NominalPValue*
Any reason 26 (8%) 39 (15%) .105
For lack of efficacy or adverse event 15 (5%) 24 (7%) .158
For lack of efficacy 5 (2%) 13 (4%) .062
  1. All data are n (%).
  2. *Nominal P-values are from Cochran-Mantel-Haenzel tests controlling for randomization stratum.
  3. FP = fluticasone propionate; ITT = intent-to-treat; SAL = salmeterol.